Indonesia Authorizes China Produced SARS-CoV-2 mRNA Vaccine
The Indonesian Food and Drugs Agency (Badan POM) recently issued an Emergency Use Authorization (EUA) for AWcorna, the Walvax-Abogen SARS-CoV-2 mRNA vaccine.
The AWcorna vaccine was developed in China by Walvax Biotechnology Co., Ltd. and Suzhou Abogen Biosciences Co., Ltd., and is authorized for adults as a two-dose primary (0.5 mL each) and those who have completed the primary series with CoronaVac® vaccines at least six months prior.
The companies announced on September 30, 2022, clinical trial results indicate the efficacy of AWcorna against symptomatic wild-type SARS-CoV-2 infection was 83.58%, and the efficacy against the Omicron variant was 71.17% in preventing moderate COVID-19 diseases.
And the administration of AWcorna in the general population showed good safety and tolerability, the most commonly reported symptoms of side effects were fever, pain at the injection site, fatigue, muscle pain, headache, chills, swelling, and itching.
"We are delighted to share the good news with everyone that obtaining the Indonesian EUA is a remarkable achievement in the commercialization stage of this product."
"Furthermore, as a proprietary mRNA vaccine independently developed in China, it is indeed proof of the effectiveness of our mRNA technology platform," commented Mr. Li Yunchun, Chairman, Walvax Biotechnology Co., Ltd., in a press release.
"Indonesia is the country with the fourth largest population and most Muslim in the world, so we believe the certified halal vaccine will be a safe, effective option for Indonesian people, which is also in alignment with their culture."
"This is the first step, and we are hoping to see more families across the country and the rest of the globe protected, which is a shared goal for us all."
Indonesia also uses mRNA COVID-19 vaccines produced by Pfizer-BioNTech and Moderna Inc.
Note: This announcement was manually translated and curated for mobile readers.
Our Trust Standards: Medical Advisory Committee